Clariane SE

ENXTPA:CLARI Stock Report

Market Cap: €662.0m

Clariane Past Earnings Performance

Past criteria checks 0/6

Clariane's earnings have been declining at an average annual rate of -50.9%, while the Healthcare industry saw earnings growing at 11.1% annually. Revenues have been growing at an average rate of 8.2% per year.

Key information

-50.9%

Earnings growth rate

-98.3%

EPS growth rate

Healthcare Industry Growth13.4%
Revenue growth rate8.2%
Return on equity-3.0%
Net Margin-2.5%
Next Earnings Update24 Feb 2025

Recent past performance updates

Recent updates

Revenues Tell The Story For Clariane SE (EPA:CLARI) As Its Stock Soars 26%

Nov 05
Revenues Tell The Story For Clariane SE (EPA:CLARI) As Its Stock Soars 26%

Here's Why Clariane (EPA:CLARI) Has A Meaningful Debt Burden

Sep 13
Here's Why Clariane (EPA:CLARI) Has A Meaningful Debt Burden

Clariane SE's (EPA:CLARI) 26% Cheaper Price Remains In Tune With Revenues

Aug 06
Clariane SE's (EPA:CLARI) 26% Cheaper Price Remains In Tune With Revenues

Here's Why It's Unlikely That Clariane SE's (EPA:CLARI) CEO Will See A Pay Rise This Year

Jun 04
Here's Why It's Unlikely That Clariane SE's (EPA:CLARI) CEO Will See A Pay Rise This Year

Clariane SE (EPA:CLARI) Shares Could Be 33% Below Their Intrinsic Value Estimate

May 22
Clariane SE (EPA:CLARI) Shares Could Be 33% Below Their Intrinsic Value Estimate

Market Participants Recognise Clariane SE's (EPA:CLARI) Revenues Pushing Shares 187% Higher

May 22
Market Participants Recognise Clariane SE's (EPA:CLARI) Revenues Pushing Shares 187% Higher

Clariane (EPA:CLARI) Takes On Some Risk With Its Use Of Debt

Apr 28
Clariane (EPA:CLARI) Takes On Some Risk With Its Use Of Debt

Is It Too Late To Consider Buying Clariane SE (EPA:CLARI)?

Dec 06
Is It Too Late To Consider Buying Clariane SE (EPA:CLARI)?

These 4 Measures Indicate That Clariane (EPA:CLARI) Is Using Debt Extensively

Oct 31
These 4 Measures Indicate That Clariane (EPA:CLARI) Is Using Debt Extensively

Calculating The Fair Value Of Clariane SE (EPA:CLARI)

Sep 21
Calculating The Fair Value Of Clariane SE (EPA:CLARI)

What Is Clariane SE's (EPA:CLARI) Share Price Doing?

Jul 29
What Is Clariane SE's (EPA:CLARI) Share Price Doing?

At €6.98, Is It Time To Put Korian (EPA:KORI) On Your Watch List?

Apr 04
At €6.98, Is It Time To Put Korian (EPA:KORI) On Your Watch List?

These 4 Measures Indicate That Korian (EPA:KORI) Is Using Debt Extensively

Mar 16
These 4 Measures Indicate That Korian (EPA:KORI) Is Using Debt Extensively

A Look At The Fair Value Of Korian (EPA:KORI)

Jan 16
A Look At The Fair Value Of Korian (EPA:KORI)

Should You Think About Buying Korian (EPA:KORI) Now?

Dec 26
Should You Think About Buying Korian (EPA:KORI) Now?

Does Korian (EPA:KORI) Have A Healthy Balance Sheet?

Dec 01
Does Korian (EPA:KORI) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Korian (EPA:KORI)?

Sep 26
Is There Now An Opportunity In Korian (EPA:KORI)?

Is Korian (EPA:KORI) A Risky Investment?

Aug 31
Is Korian (EPA:KORI) A Risky Investment?

Why Korian (EPA:KORI) Could Be Worth Watching

Jun 14
Why Korian (EPA:KORI) Could Be Worth Watching

We Think Korian (EPA:KORI) Is Taking Some Risk With Its Debt

Mar 30
We Think Korian (EPA:KORI) Is Taking Some Risk With Its Debt

Korian (EPA:KORI) Has A Somewhat Strained Balance Sheet

Dec 24
Korian (EPA:KORI) Has A Somewhat Strained Balance Sheet

Korian (EPA:KORI) Seems To Be Using A Lot Of Debt

Sep 25
Korian (EPA:KORI) Seems To Be Using A Lot Of Debt

Why Korian (EPA:KORI) Could Be Worth Watching

Jul 15
Why Korian (EPA:KORI) Could Be Worth Watching

Revenue & Expenses Breakdown

How Clariane makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

ENXTPA:CLARI Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 245,170-1295650
31 Mar 245,083-1115550
31 Dec 234,996-925450
30 Sep 234,865-325270
30 Jun 234,735285090
31 Mar 234,587324830
31 Dec 224,438364580
30 Jun 224,288854390
31 Mar 224,212924340
31 Dec 214,1371004300
30 Sep 214,047764040
30 Jun 213,941604250
31 Mar 213,857504310
31 Dec 203,773394370
30 Sep 203,728574460
30 Jun 203,683744560
31 Mar 203,648944520
31 Dec 193,6131154490
30 Sep 193,5421175280
30 Jun 193,4711196070
31 Mar 193,4041216860
31 Dec 183,3361237650
30 Sep 183,2801527550
30 Jun 183,2241807440
31 Mar 183,1771727390
31 Dec 173,1311637350
30 Sep 173,0911507360
30 Jun 173,0521377380
31 Mar 173,0171347330
31 Dec 162,9811317280
30 Sep 162,880877060
30 Jun 162,779426840
31 Mar 162,676506740
31 Dec 152,573596640
30 Sep 152,553776640
30 Jun 152,533956640
31 Mar 152,378786310
31 Dec 142,222615970
30 Sep 141,938445260
30 Jun 141,654274550
31 Mar 141,505284230
31 Dec 131,356293910

Quality Earnings: CLARI is currently unprofitable.

Growing Profit Margin: CLARI is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CLARI is unprofitable, and losses have increased over the past 5 years at a rate of 50.9% per year.

Accelerating Growth: Unable to compare CLARI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLARI is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (15.5%).

Return on Equity

High ROE: CLARI has a negative Return on Equity (-2.99%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 19:54
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Clariane SE is covered by 22 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Armelle MoulinAlphaValue
Fraser DonlonBerenberg
Laurent GelebartBNP Paribas Exane